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Abstract
Introduction: The Rho family GTPase Rac1 regulates cytoskeletal rearrangements crucial for the recruitment, 
extravasation and activation of leukocytes at sites of inflammation. Rac1 signaling also promotes the activation and 
survival of lymphocytes and osteoclasts. Therefore, we assessed the ability of a cell-permeable Rac1 carboxy-terminal 
inhibitory peptide to modulate disease in mice with collagen-induced arthritis (CIA).
Methods: CIA was induced in DBA/1 mice, and in either early or chronic disease, mice were treated three times per 
week by intraperitoneal injection with control peptide or Rac1 inhibitory peptide. Effects on disease progression were 
assessed by measurement of paw swelling. Inflammation and joint destruction were examined by histology and 
radiology. Serum levels of anti-collagen type II antibodies were measured by enzyme-linked immunosorbent assay. T-
cell phenotypes and activation were assessed by fluorescence-activated cell sorting analysis. Results were analyzed 
using Mann-Whitney U and unpaired Student t tests.
Results: Treatment of mice with Rac1 inhibitory peptide resulted in a decrease in paw swelling in early disease and to a 
lesser extent in more chronic arthritis. Of interest, while joint destruction was unaffected by Rac1 inhibitory peptide, 
anti-collagen type II antibody production was significantly diminished in treated mice, in both early and chronic 
arthritis. Ex vivo, Rac1 inhibitory peptide suppressed T-cell receptor/CD28-dependent production of tumor necrosis 
factor α, interferon γ and interleukin-17 by T cells from collagen-primed mice, and reduced induction of ICOS and 
CD154, T-cell costimulatory proteins important for B-cell help.
Conclusions: The data suggest that targeting of Rac1 with the Rac1 carboxy-terminal inhibitory peptide may suppress 
T-cell activation and autoantibody production in autoimmune disease. Whether this could translate into clinically 
meaningful improvement remains to be shown.
Introduction
Rheumatoid arthritis (RA) is marked by de-regulated
recruitment, activation, and retention of inflammatory
white blood cells in affected joints [1]. Subsequent autoan-
tibody production, release of cytokines, and cell-cell con-
tacts may perpetuate inflammation and lead to joint
destruction through activation of stromal fibroblast-like
synoviocytes (FLSs) and osteoclasts [2]. Many of the cellu-
lar processes required for perpetuation of inflammation and
joint destruction in RA are regulated by Rac GTPases,
members of the Rho-like family of small GTPase signaling
proteins [3].
Rac1 is ubiquitously expressed in mammalian tissues,
whereas expression of Rac2 is limited to cells of
hematopoietic lineage [4,5]. Rac GTPases are activated by
a broad array of extracellular stimuli relevant to RA,
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including chemokines, lymphocyte antigen receptor liga-
tion, inflammatory cytokines, and cell-cell adhesion [6-11].
Following activation, Rac proteins initiate multiple signal-
ing pathways that regulate cytoskeletal rearrangements,
kinase cascades needed for gene transcription, and assem-
bly of the NADPH oxidase [6,12]. Transfection of active
and dominant-negative mutants of Rac1 as well as genetic
studies have demonstrated that lymphocytes and neutro-
phils require Rac1 signaling for efficient polarized chemot-
actic responses and trafficking in vivo [13-19]. Although
macrophages do not require Rac1 and Rac2 function for
chemotactic responses, macrophage invasion of tissue is
dependent upon Rac1 and Rac2 [20]. Rac signaling is also
important for productive interactions between lymphocytes
and antigen-presenting cells (APCs). After antigen recogni-
tion by T cells, ezrin-radixin-moesin proteins are dephos-
phorylated through a Rac1-dependent pathway, favoring
relaxation of the cytoskeleton and subsequently promoting
T cell-APC conjugate formation [21]. Reciprocally, Rac
activity in dendritic cells (DCs) is required for effective
antigen presentation to T cells and subsequent T-cell prim-
ing [22]. Antigen receptor-dependent activation of Rac sig-
naling also stimulates activation of mitogen-activated
protein kinase, phosphatidylinositol 3-kinase, and nuclear
factor-kappa-B signaling pathways important for lympho-
cyte activation, proliferation, and survival [7-9]. Many of
these downstream signaling pathways are now being
explored as potential therapeutic targets in RA [23]. Rac
proteins also serve additional important functions in cells of
myeloid lineage which contribute to inflammation and joint
destruction in RA. Oxidative bursts of macrophages and
neutrophils rely upon Rac1-dependent assembly of the
NADPH oxidase machinery [12]. Additionally, in vitro
studies of osteoclasts transfected with plasmid encoding
dominant-negative Rac and in vivo studies in Rac-deficient
mice have identified essential but redundant roles for Rac1
and Rac2 proteins in osteoclastogenesis, osteoclast motility,
and bone resorption [24,25].
Together, these studies indicate that therapeutic strategies
targeting Rac1 function may be of clinical benefit in RA.
However, preclinical assessment of Rac1 inhibition has
been hampered by a lack of compounds specifically target-
ing Rac1 and by limited analyses of Rac1 in animal models
of arthritis, a consequence of early findings demonstrating
that genetic deletion of Rac1 in mice results in early embry-
onic lethality [26]. NSC23766, a pharmacological com-
pound that inhibits Rac GTPases via targeting of the
activating guanine nucleotide exchange factors Tiam1 and
Trio, suppresses RA FLS proliferation and invasiveness in
vitro, effects mimicked by siRNA (short interfering RNA)
silencing of Rac1 expression in these cells [27]. This may
indicate that specific inhibition of Rac1 may be therapeuti-
cally beneficial in RA. However, mice in which Rac1 has
been conditionally deleted in mature neutrophils and mac-
rophages on a Rac2-deficient background show a complex
phenotype in a Chlamydia-induced infection model of
arthritis [28]. In these animals, Rac1 has a bimodal effect
on disease progression. In the acute phase, Rac1 deficiency
delays recruitment and activation of inflammatory neutro-
phils in the joint, whereas in the chronic phase, disease is
exacerbated due to an inability of neutrophils to clear the
pathogen. In this study, we targeted Rac1 in mice with col-
lagen-induced arthritis (CIA), using a Rac1-specific cell-
permeable carboxy-terminal inhibitory peptide that we have
previously shown to block Rac1 function in human lym-
phocytes, endothelial cells, and epithelial cells [11,29,30].
Materials and methods
Animals
Male DBA/1 mice were purchased from Harlan (Horst, The
Netherlands), housed under conventional conditions at the
animal facility of the Academic Medical Center (Amster-
dam, The Netherlands), and fed ad libitum. The animal eth-
ical committee of the Academic Medical Center approved
all experiments.
Peptide synthesis
For this study, peptides encoding a protein transduction
domain [31] alone (indicated as control, Ctrl, throughout
the article) or fused to the carboxy-terminal domain of
Rac1, excluding the Rac1 CAAX box (indicated as Rac1
throughout this article), were synthesized using N-(9-fluo-
renyl)methoxycarbonyl (fMoc) solid-phase chemistry [29].
Peptide synthesis was performed using a Syro II (MultiSyn-
Tech GmbH, Witten, Germany).
T-cell isolation
Murine spleens were crushed through a 40-μm cell strainer
(BD Biosciences Pharmingen, San Diego, CA, USA) to
obtain single-cell suspensions. Erythrocytes were lysed
with ice-cold isotonic NH4Cl solution (155 mM NH4Cl, 10
mM KHCO3, and 100 mM ethylenediaminetetraacetic acid
[EDTA], pH 7.4). To purify T cells, splenic cell suspensions
were incubated with anti-murine CD4 and CD8 antibody-
coated magnetic microbeads (Miltenyi Biotec, Bergisch
Gladbach, Germany) for 20 minutes at 4°C and positively
selected by magnetic separation with magnetic-activated
cell sorting. Purified T cells were more than 90% CD3+ as
analyzed by flow cytometry.
Actin polymerization assays
Actin polymerization assays were performed as previously
described [32]. Briefly, purified T cells were preincubated
for 15 minutes in medium containing 200 μg/mL Ctrl or
Rac1 peptide. T cells were then exposed to 100 ng/mL
stromal cell-derived factor 1 alpha (SDF-1α), and at the
indicated time points, 100-μL aliquots of cell suspensionsAbreu et al, Arthritis Research & Therapy 2010, 12:R2
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were transferred to an equivalent volume of fixation solu-
tion (Intraprep Fixation Reagent; Coulter Immunotech,
Marseille, France). After 15 minutes, cells were washed in
0.5% bovine serum albumin/phosphate-buffered saline
(PBS) and resuspended in 100 μL of permeabilization
reagent (Coulter Immunotech) for 5 minutes. Cells were
stained for 20 minutes with 1 unit/mL Alexa 488 Phalloidin
(Molecular Probes Inc., now part of Invitrogen Corpora-
tion, Carlsbad, CA, USA) to visualize F-actin. The mean
fluorescence intensity (MFI) of polymerized actin was mea-
sured by flow cytometry (BD Biosciences Pharmingen),
and the fold increase in actin polymerization was calculated
by dividing the MFI generated at a particular time point by
the MFI at t = 0 of that particular condition.
Induction and assessment of CIA
Bovine collagen type II (bCII) (2 mg/mL in 0.05 M acetic
acid; Chondrex, Inc., Redmond, WA, USA) was mixed with
complete Freund's adjuvant (CFA) (2 mg/mL of Mycobac-
terium tuberculosis; Chondrex, Inc.) and injected intrader-
mally on day 0 at the base of the tail with 100 μL of
emulsion into 8- to 11-week-old mice. On day 21, mice
received an intraperitoneal booster injection with 100 μg of
bCII in PBS. To investigate the treatment efficacy of Rac1
peptide at disease onset, mice were treated at day 20 with 2
mg, 1 mg, or 0.5 mg of Ctrl or Rac1 peptide three times
weekly until sacrifice. To assess the effects of Ctrl and Rac1
peptides on lymphocyte trafficking, phenotype, and activa-
tion, a separate experiment in which 16 mice were injected
with bCII in CFA at day 0 as above was performed. On day
19, the mice were randomly assigned, and six mice were
sacrificed to obtain splenocytes. The remaining mice were
treated with 2 mg of Ctrl or Rac1 peptide (n = 5 for each
group) starting from day 20 and were boosted with bCII on
day 21, followed by additional treatment with peptide on
days 22, 25, and 27. On day 28, mice were sacrificed and
blood and spleens were harvested. Alternatively, to explore
the effect of Rac1 peptide treatment in chronic disease, the
animals were randomly assigned at day 29 to one of two
groups and treated intraperitoneally with 4 mg of Ctrl or
Rac1 peptide. Treatments were continued three times
weekly until sacrifice at day 39. The severity of arthritis
was assessed in a blinded manner using a semiquantitative
scoring system (0 to 4): 0, normal; 1, redness or swelling or
both in one joint; 2, redness or swelling or both in more
than one joint; 3, redness or swelling or both in the entire
paw; and 4, deformity or ankylosis or both. Hind paw ankle
joint thickness was measured using a dial caliper (POCO
2T 0- to 10-mm test gauge; Kroeplin Längenmesstechnik,
Schlüchtern, Germany). Experiments were performed using
8 to 16 mice per group.
Histological analysis
Hind paws were fixed in 10% buffered formalin for 48
hours and decalcified in 15% EDTA. The paws were then
embedded in paraffin, and 5-μm saggital serial sections of
whole hind paws were cut. Tissue sections were stained
with hematoxylin and eosin. Inflammation was graded on a
scale from 0 (no inflammation) to 3 (severely inflamed
joint) based on infiltration of the synovium by inflamma-
tory cells. Cartilage erosion was scored using a semiquanti-
tative scoring system from 0 (no erosions) to 3 (extended
erosions). The tissue was examined by microscopic evalua-
tion in a blinded manner by two independent observers
(JRFA and MJV).
Radiological analysis
Hind paws were used for radiographic evaluation. Two
observers without knowledge of the treatment groups
scored the x-rays. Joint destruction was scored on a scale
from 0 to 4: 0, no damage; 1, minor bone destruction
observed in one enlightened spot; 2, moderate changes, two
to four spots in one area; 3, severe erosions afflicting the
joint; and 4, complete destruction of the joints.
Determination of anti-collagen antibodies by enzyme-
linked immunosorbent assay
Maxisorb 96-well plates (Nunc, Roskilde, Denmark) were
coated with 5 μg/mL of bCII in 0.1 M sodium carbonate
buffer (pH 9.7) overnight at 4°C. After blocking for 1 hour
with 2% milk in PBS at room temperature, sera were added
in serial dilutions in 2% milk/PBS and incubated overnight
at 4°C. Plates were subsequently washed and incubated
with 1 μg/mL biotinylated rat anti-mouse immunoglobulin
(Ig) (SouthernBiotech, Birmingham, AL, USA) of the indi-
cated isotype in 2% milk/PBS for 1 hour at room tempera-
ture. After washing, plates were incubated with
streptavidin-conjugated alkaline phosphatase (Stratech Sci-
entific Limited, Newmarket, Suffolk, UK) for 1 hour at
room temperature, washed, and developed with p-nitrophe-
nyl phosphate substrate (Sigma-Aldrich, St Louis, MO,
USA). The reaction was stopped with 2 M H2SO4, and opti-
cal density at 415 nm was measured.
B- and T-cell phenotyping
Splenocytes were obtained as above. White blood cells
were obtained from approximately 100 μL of blood follow-
ing heart puncture. Erythrocytes were removed by lysis in
isotonic NH4Cl solution and the remaining white blood
cells were counted prior to staining. Antibodies from eBio-
science, Inc. (San Diego, CA, USA) used in this study
included the following: anti-CD3-fluorescein isothiocya-
nate (FITC), -APC; anti-B220-FITC, -APC; anti-CD8-phy-
coerythrin (PE), -FITC, -Alexa 780; anti-CD44-FITC, -
PerCP Cy5.5; anti-CD62L-APC, -PeCY7; anti-Foxp3-PE, -
APC; anti-interleukin (IL)-17-Alexa 488; anti-tumor necro-Abreu et al, Arthritis Research & Therapy 2010, 12:R2
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sis factor alpha (TNFα)-APC, -PE; and anti-ICOS-PE and
anti-CD154-APC. Anti-CD4-FITC, anti-CD4-PE, and anti-
IL-2-APC were from BD Biosciences Pharmingen. For
phenotyping, splenocytes and white blood cells were
stained with the indicated fluorochrome-conjugated anti-
bodies. To assess T-cell cytokine expression, splenocytes
obtained from mice on day 19 following immunization with
bCII in CFA immunization were pretreated for 15 minutes
with 200 μg/mL Ctrl and Rac1 peptides, followed by? stim-
ulation for 24 hours with plate-bound anti-CD3 (5 μg/mL)
and soluble anti-CD28 (5 μg/mL) antibodies (both gener-
ously provided by Dr Louis Boon, Bioceros BV, Utrecht,
The Netherlands). During the last 4 hours of stimulation,
brefeldin A (10 μg/mL; Sigma-Aldrich) was added to the
splenocyte cultures. Cells were harvested and stained with
CD3, CD4, and CD8 antibodies, followed by fixation, per-
meabilization with Cytofix/Cytoperm (BD Biosciences
Pharmingen), and labeling for intracellular cytokines.
Treatment of cells with brefeldin A and permeabilization
were omitted in assessment of ICOS and CD154 expres-
sion. Cell marker expression and cytokine expression were
detected using a FACS [fluorescence-activated cell sorting]
Calibur flow cytometer (BD Biosciences Pharmingen) and
CellQuest Pro software (BD Biosciences Pharmingen).
Statistical analysis
To evaluate the effects of different treatments, we deter-
mined the change in paw swelling scores (delta) of each
mouse from the start of treatment until the end of the exper-
iment. Areas under the curve were calculated for the delta
paw swelling. The significance of the differences in delta
paw swelling, radiological, and histological scores between
groups was determined using the unpaired Student t test.
Potential differences in T- and B-lymphocyte surface
marker expression and cytokine production were deter-
mined using a Mann-Whitney U test. P values of not more
than 0.05 were considered statistically significant.
Results
The Rac1 inhibitory peptide blocks murine T-cell actin 
polymerization
The Rac1 peptide is able to block endogenous Rac1 signal-
ing within minutes by competing with Rac1 effector pro-
teins and, in vitro, has been demonstrated to possess a
potent capacity to block actin polymerization and migration
of human cells stimulated with SDF-1α [11,29,30]. The bio-
logical activity of the peptide batches used for in vivo
experiments and their ability to influence murine cellular
responses were first examined in an actin polymerization
assay using murine splenic T cells. Pretreatment of murine
T cells with Rac1 peptide, but not Ctrl peptide, completely
blocked actin polymerization following SDF-1α stimula-
tion, as measured by increases in T-cell F-actin content
(Figure 1a, b). This indicated that the Rac1 peptide was
effective in blocking Rac1 signaling not only in human
cells but in murine cells as well.
Rac1 inhibitory peptide treatment reduces paw swelling 
and anti-bCII antibody production in early arthritis
After confirming the in vitro efficiency of the Rac1 peptide
in inhibiting murine Rac1 signaling, we examined the in
vivo potential of this peptide when mice are treated at the
onset of disease. One day before the booster at day 20, we
started treatment of the animals with 2 mg, 1 mg, or 0.5 mg
of Ctrl or Rac1 peptide three times weekly until sacrifice.
Treatment of animals with Rac1 peptide at all doses failed
to influence clinical scores of disease severity or animal
weight (data not shown), but animals treated with 2 mg of
Rac1 peptide showed a highly significant decrease in paw
swelling when compared with treatment with Ctrl peptide
(61% reduction, P = 0.009) (Figure 2a, b). The effect was
dose-dependent; treatment with lower doses of Rac1 pep-
tide showed a trend toward improvement, and this trend did
not reach statistical significance (Figure 2a, b). Administra-
tion of Rac1 peptide had no significant effects on disease
incidence or onset in these experiments (Figure 2c).
We further examined mice treated with 2 mg of Ctrl and
Rac1 peptides for other disease parameters. Quantification
of synovial inflammation revealed a minor decrease in cel-
lularity, but this decrease did not reach statistical signifi-
cance (Figure 3a). Treatment with Rac1 peptide did not
protect against joint destruction (Figure 3b, c). Finally, we
examined the influence of Rac1 peptide on anti-bCII anti-
body production. We collected sera from mice at the time of
sacrifice and measured specific anti-bCII antibody levels by
enzyme-linked immunosorbent assay. Mice treated with 2
mg of Rac1 peptide showed a significant reduction in the
serum levels of anti-bCII IgG1 (Ctrl 100% ± 12.9%; Rac1
62.1% ± 11.8%; P < 0.05) and IgG2a (Ctrl 100% ± 2.7%;
Rac1 83.3% ± 6.8%; P = 0.05) antibodies compared with
mice treated with Ctrl peptide (Figure 3d).
Treatment of chronic CIA with Rac1 peptide reduces anti-
bCII antibody production
We next investigated the effect of Rac1 peptide treatment
on mice with chronic arthritis. For this, we performed an
independent CIA experiment wherein 29 days after the ini-
tial immunization, mice having clinical signs of arthritis
were randomly assigned to one of two groups. Mice within
groups were treated with 4 mg of Ctrl or 4 mg of Rac1 pep-
tide three times weekly until sacrifice. Administration of
Rac1 peptide had no influence on clinical disease severity
(data not shown). However, we observed a clear trend
toward reduced paw swelling in mice treated with Rac1
peptide (Figure 4a, b) in two independent experiments,
although the differences did not reach statistical signifi-
cance (experiment 1: 49% reduction, P = 0.528; experiment
2: 22% reduction, P = 0.193) (Figure 4b).Abreu et al, Arthritis Research & Therapy 2010, 12:R2
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The Rac1 carboxy-terminal peptide efficiently blocks actin polymerization in murine cells Figure 1 The Rac1 carboxy-terminal peptide efficiently blocks actin polymerization in murine cells. (a) Representative histograms of F-actin 
staining in T cells isolated from mice spleens that were exposed for 15 minutes to 200 μg/mL of Ctrl or Rac1 peptide followed by stromal cell-derived 
factor 1 (SDF-1) stimulation. (b) Fold increase in F-actin. Data are depicted as mean fold increase (MFI) of F-actin ± standard error of the mean (n = 3). 
*P < 0.05. Ctrl, control.
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We also analyzed the effects of the Rac1 peptide on syn-
ovial inflammation, cartilage degradation, and bone
destruction in this model. Consistent with the trend toward
reduced paw swelling, there was a trend toward decreased
histological signs of inflammation and cartilage destruc-
tion, but this trend did not reach statistical significance
(Figure 4c, d). Analysis of x-rays taken from the mice paws
revealed that Rac1 peptide treatment did not protect against
erosive disease (Figure 4e). However, Rac1 peptide treat-
ment of mice with chronic arthritis resulted in a significant
reduction in the serum levels of anti-bCII IgG2a (Ctrl 100%
± 5.6%; Rac1 81.6% ± 6.5%; P = 0.05) and IgG2b (Ctrl
100% ± 10.9%; Rac1 56.0% ± 6.7%; P < 0.005), whereas
no differences were observed for IgG1 or IgG3 (Figure 4f).
Rac1 peptide does not alter the distribution or phenotype 
of lymphocytes during the onset of arthritis
To better understand how Rac1 peptide might influence
paw swelling and autoantibody formation during the onset
of CIA, we examined the distribution of B and T lympho-
cytes in mice shortly after disease onset. Mice were immu-
nized with bCII in CFA, and one day before administrating
a second immunization with bCII on day 20, we randomly
assigned the mice and initiated treatment with 2 mg of Ctrl
or Rac1 peptide (n = 5 mice per group). Mice were treated
with peptides three times weekly until sacrifice on day 28.
Total numbers and percentages of B and T lymphocytes in
blood (Figure 5a) and spleens (Figure 5b) were then
assessed. As compared with mice treated with Ctrl peptide,
Rac1 peptide exerted no effect on either the percentages
(left panels) or total numbers (right panels) of CD3+ T lym-
Reduced paw swelling, but no effect on disease incidence, after treatment with 2 mg of Rac1 carboxy-terminal peptide Figure 2 Reduced paw swelling, but no effect on disease incidence, after treatment with 2 mg of Rac1 carboxy-terminal peptide. Mice were 
treated with 2 mg, 1 mg, or 0.5 mg of Ctrl (white square) or Rac1 (black square) peptide at the indicated time points. Paw swelling and inflammation 
of the four limbs were determined for each mouse. (a) Delta hind paw ankle joint swelling was calculated by subtracting the paw diameter on the 
day of initiation of treatment from the measured diameter. Values are presented as mean ± standard error of the mean (SEM) (n = 8). (b) Area under 
the curve (AUC) was calculated for the delta paw swelling in each mouse. Values are presented as mean AUC ± SEM. *P < 0.05. (c) Cumulative inci-
dence of arthritis in mice for each dosage of Ctrl and Rac1 peptide was calculated. Ctrl, control.
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phocytes (upper panels) or B220+ B lymphocytes (lower
panels). We also addressed the possibility that Rac1 peptide
may regulate the distribution or differentiation of distinct T-
cell subsets during the onset of CIA (Figure 6). However,
we observed no differences between Ctrl peptide- and Rac1
peptide-treated mice in regard to CD4+ and CD8+ percent-
ages in blood (Figure 6a, left panel) or in terms of the distri-
bution of CD4+ (middle panel) or CD8+ (right panel) CD44-
CD62L+  naïve, CD44+CD62L-  effector/memory, or
CD44+CD62L+ central memory T cells. Small increases in
the percentages of CD4+ (P < 0.05) and CD8+ (P < 0.01)
central memory T cells were observed in the spleens of
Effects of treatment with the Rac1 carboxy-terminal peptide at onset of disease in collagen-induced arthritis Figure 3 Effects of treatment with the Rac1 carboxy-terminal peptide at onset of disease in collagen-induced arthritis. Mice were treated 
with 2 mg of Ctrl (white bars) or 2 mg of Rac1 (black bars) peptide starting at day 20. After sacrifice, sections from mice paws (n = 8 per group) were 
stained with hematoxylin and eosin and assessed for (a) cellular infiltration and (b) cartilage erosion. (c) X-rays of hind paws were analyzed for bone 
damage. (d) Sera from mice that started treatment at day 20 (n = 8) with Ctrl (white bars) or Rac1 (black bars) peptide were collected, and the levels 
of specific anti-collagen IgG were detected. IgG levels in the sera of Ctrl-treated mice were set to 100%, and the levels obtained in the sera of Rac1-
treated mice were then calculated relative to Ctrl. Represented IgG values were calculated within linear regions of the serum dilution curve. All values 
are presented as mean ± standard error of the mean. *P ≤ 0.05. Ctrl, control.
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mice treated with Rac1 peptide, but reciprocal decreases in
other T-cell subsets were not evident (Figure 6b). No differ-
ences in the percentages of splenic FoxP3+ regulatory T
cells were observed (data not shown).
Rac1 peptide suppresses T-cell receptor-dependent 
inflammatory cytokine production and T-cell costimulatory 
protein expression
Our analysis of B- and T-lymphocyte distribution in mice
during CIA onset failed to reveal a prominent effect of
Rac1 peptide on lymphocyte trafficking, and synovial cellu-
lar infiltration scores were similar in mice treated with Ctrl
and Rac1 peptides (Figure 3a). We therefore examined
whether the effect of the Rac1 peptide on autoantibody pro-
duction might reflect effects on T-cell activation. Mice (n =
5) were immunized with bCII and CFA and sacrificed on
day 19. Splenocytes isolated from the mice were then stim-
ulated with anti-CD3/CD28 antibodies in the presence of
Ctrl or Rac1 peptide. Intracellular staining and FACS analy-
sis revealed no effect of Rac1 peptide on T-cell IL-2 pro-
duction (Figure 7). However, Rac1 peptide significantly
decreased the percentages of T cells capable of responding
to CD3/CD28 stimulation by production of other T-cell
cytokines important in CIA and RA. Significant reductions
in the percentages of CD4+ T cells producing TNFα (P <
0.05), interferon-gamma (IFNγ)-producing CD8+ T cells (P
< 0.05), and IL-17-producing CD4+ and CD8+ T cells (P <
0.05) were observed. We also examined the effect of the
Rac1 peptide on the induced expression of T-cell costimula-
tory proteins, ICOS and CD154, which play crucial roles in
CD4+ T-cell help to B cells needed for autoantibody produc-
tion in CIA [33-36]. Although Rac1 peptide had no influ-
ence on the percentages of CD3+CD4+  splenocytes
expressing ICOS and CD154 following anti-CD3/CD28
stimulation (Figure 8a), significant reductions in the
amount of ICOS (P  < 0.05) and CD154 (P  < 0.01)
expressed on the T-cell surface were observed following
Rac1 peptide treatment (Figure 8b). Thus, interference with
T-cell Rac1 signaling directly interferes with the ability of
T cells to produce inflammatory cytokines and express
Effect of Rac1 carboxy-terminal peptide treatment of mice with chronic arthritis Figure 4 Effect of Rac1 carboxy-terminal peptide treatment of mice with chronic arthritis. (a) Delta hind paw ankle joint swelling of mice that 
started treatment at day 29 with 4 mg of Ctrl or Rac1 peptide (three times weekly). Values are representative of two independent experiments (n = 16 
per group). (b) Area under the curve (AUC) calculated as in Figure 2b. Paraffin-embedded sections of the hind paws were stained with hematoxylin 
and eosin and analyzed for (c) synovial inflammation and (d) cartilage destruction. (e) X-rays were analyzed for bone damage (n = 16 per group). (f) 
Sera from mice that started treatment at day 29 (n = 7) with Ctrl (white bars) or Rac1 (black bars) peptide were collected, and the levels of specific anti-
collagen IgG were detected. IgG levels in the sera of Ctrl-treated mice were set to 100%, and the levels obtained in the sera of Rac1 peptide-treated 
mice were then calculated relative to Ctrl. Represented values were calculated within linear regions of the serum dilution curve. All values are ex-
pressed as mean ± standard error of the mean. *P ≤ 0.05. Ctrl, control.
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Effect of Rac1 carboxy-terminal peptide treatment of mice on lymphocyte numbers and percentages in blood and spleen Figure 5 Effect of Rac1 carboxy-terminal peptide treatment of mice on lymphocyte numbers and percentages in blood and spleen. Mice 
treated with Ctrl or Rac1 peptide (2 mg, n = 5 per group) were sacrificed on day 28 following arthritis induction, and CD3+ T cells and B220+ B cells 
were identified by fluorescence-activated cell sorting analysis in (a) blood and (b) spleen. Numbers of CD3+ T cells (upper panels) and B220+ cells (low-
er panels) were calculated as percentage positive cells (left panels) or total number of cells (right panels) per milliliter of blood or per spleen. Data 
points within each column represent individual mice, and the bar indicates the median value. Ctrl, control.
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T-cell phenotyping in arthritic mice treated with Rac1 carboxy-terminal peptide Figure 6 T-cell phenotyping in arthritic mice treated with Rac1 carboxy-terminal peptide. Blood (a) and spleens (b) were obtained from arthrit-
ic mice treated with Ctrl or Rac1 peptide (2 mg, n = 5 per group), and cells were stained with antibodies against CD3, CD4, CD8, CD44, and CD62L. 
The percentages of CD3+ T cells expressing CD4 and CD8 (left panels) and naïve (CD44-CD62L+), central memory (CM) (CD44+CD62L+), and effector/
memory (EM) (CD44+CD62L-) CD3+CD4+ (middle panels) and CD3+CD8+ T cells were calculated. Data points within each column represent individual 
mice, and the bar indicates the median value. *P ≤ 0.05, *P ≤ 0.01. Ctrl, control.
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costimulatory proteins required for the promotion of
autoantibody responses.
Discussion
In this report, we provide evidence that the inhibitory Rac1
carboxy-terminal peptide suppresses anti-collagen antibody
production associated with reduced paw swelling in mice
with CIA. We have found that the administration of Rac1
peptide in vivo, either as an early treatment or as treatment
of mice with more chronic arthritis, results in a significant
reduction of circulating levels of anti-bCII IgG1 and IgG2a
or IgG2a and IgG2b antibodies, respectively, depending on
the stage of the disease. In both early and chronic arthritis,
there was an effect on IgG2a levels. In many murine in vivo
model systems, IgG2a and IgG2b antibodies display greater
pro-inflammatory properties than IgG1 and IgG3 [37]. Ini-
Effect of Rac1 carboxy-terminal peptide treatment on T-cell cytokine production Figure 7 Effect of Rac1 carboxy-terminal peptide treatment on T-cell cytokine production. Splenocytes obtained from mice (n = 6) on day 19 
following priming with bovine collagen type II in complete Freund's adjuvant were preincubated for 15 minutes with Ctrl or Rac1 peptide (200 μg/
mL) and stimulated for 24 hours with anti-CD3 and anti-CD28 antibodies. Brefeldin A was included for the last 4 hours of stimulation, and cells were 
stained for CD3, CD4, CD8, interleukin (IL)-2, tumor necrosis factor-alpha (TNFα), interferon-gamma (IFNγ), and IL-17. The percentages of CD3+CD4+ 
and CD3+CD8+ T cells expressing each cytokine were determined by fluorescence-activated cell sorting analysis. Data points within each column rep-
resent values obtained from splenocytes of individual mice, and the bar indicates the median value. *P ≤ 0.05. Ctrl, control.
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tial evidence presented here indicates that Rac1 inhibitory
peptide exerts its protective effect at least in part through
interference with T-cell receptor (TCR)/CD28 signals
needed for T-cell expression of inflammatory cytokines as
well as for expression of costimulatory proteins required for
B-cell activation.
It is unlikely that the suppressive effect of Rac1 peptide
on paw swelling and anti-collagen antibody production
observed in our studies is due to inhibitory effects on
immune cell trafficking. First, we noted no significant dif-
ferences in cellular infiltration of the synovium in Ctrl and
Rac1 peptide-treated mice. Second, the Rac1 peptide did
not influence the numbers or percentages of B and T lym-
phocytes in blood or spleen during CIA. These results are
consistent with genetic studies indicating that Rac1 and
Rac2 play redundant roles in lymphocyte and myeloid cell
trafficking, reflecting the high specificity of the Rac1 pep-
tide for interfering with signaling from Rac1 but not other
Rho family GTPases [29]. Murine neutrophils express both
Rac1 and Rac2, and genetic deletion of each GTPase has
revealed their important but redundant contributions to neu-
trophil chemotactic responses in vitro and in vivo [18,19].
Rac1-deficient murine neutrophils retain chemokinetic
responses but are unable to orient and migrate toward
chemokine gradients. In contrast, Rac2 is required for effi-
cient neutrophil migration [19]. Although similar direct
comparative analyses have not been performed on B and T
cells in these mice, initial studies indicate that lymphocyte
trafficking is regulated primarily by Rac2 [15].
Surprisingly, we observed little if any effect of Rac1 pep-
tide on cartilage and joint destruction in murine arthritis,
although a significant decrease in paw swelling was
observed in mice when treated at the onset of disease, and a
reproducible trend toward reduced paw swelling was noted
in mice treated with Rac1 peptide at a more chronic phase
of disease. Decreases in paw swelling after treatment with
Rac1 peptide which we observed might be due to effects on
the formation of edema. Experiments conducted in vitro
have demonstrated that exposure of human endothelial cells
to reactive oxygen species or engagement of the integrin
ligand VCAM (vascular cell adhesion molecule) leads to
Rac1-dependent loss of cadherin-mediated endothelial cell-
cell adhesion. In the presence of the Rac1 peptide, endothe-
lial cell-cell adhesion is maintained (data not shown)
[11,38]. A role for Rac1 in maintaining vascular endothelial
integrity in vivo is also indirectly suggested in studies of c-
Jun knockout mice, in which inhibition of c-Jun, a down-
stream target of Rac signaling, suppresses edema, paw
swelling, and inflammation in an experimental model of
arthritis [39]. Lack of effect of Rac1 peptide on joint
destruction in CIA may reflect a redundant role for Rac2 in
supporting osteoclastogenesis [24,25].
Rac1 inhibitory peptide may inhibit anti-bCII antibody
production in CIA via one or more mutually non-exclusive
Effect of Rac1 carboxy-terminal peptide treatment on T-cell  costimulatory protein expression Figure 8 Effect of Rac1 carboxy-terminal peptide treatment on T-
cell costimulatory protein expression. Splenocytes from mice 
primed with bovine collagen type II in complete Freund's adjuvant an-
alyzed in Figure 7 (n = 6) were examined for ICOS and CD154 expres-
sion by fluorescence-activated cell sorting analysis following 24-hour 
stimulation with anti-CD3 and anti-CD28 antibodies in the presence of 
Ctrl or Rac1 peptide (200 μg/mL). The percentages of CD3+CD4+ T cells 
expressing CD154 and ICOS (a) and the mean geometric (geomean) 
fluorescence intensity (mfi) of CD154 and ICOS expression on these 
cells (b) were calculated following fluorescence-activated cell sorting 
analysis. Data points within each column represent values obtained 
from splenocytes of individual mice, and the bar indicates the median 
value. *P ≤ 0.05; **P < 0.01. Ctrl, control.
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mechanisms. It is unlikely that Rac1 inhibition directly
interferes with B-cell activation as Rac1 and Rac2 make
critically redundant contributions to the transduction of B-
cell receptor signals required for both survival and efficient
cell cycle entry [9,40]. Rac2 deletion in mice results in
decreased B-cell maturation and T cell-independent antigen
responses [14,15]. In contrast, conditional deletion of Rac1
in the B-cell compartment has no observable effect on B-
cell maturation or function unless Rac2 is simultaneously
deleted [40]. Similarly redundant but critical roles for Rac1
and Rac2 are observed during T-cell maturation and prolif-
erative responses to TCR triggering [17]. Consistent with
this, we observed no effect of Rac1 inhibitory peptide on
TCR/CD28-induced T-cell IL-2 production ex vivo. How-
ever, we did note that Rac1 inhibition decreased the ability
of T cells to produce the inflammatory cytokines TNFα,
IFNγ, and IL-17 in response to TCR/CD28 triggering.
These findings bear similarities with a recent report that thi-
onamides interfere with human T-cell TNFα and IFNγ pro-
duction via inhibition of Rac1 activation [41]. Interference
with anti-bCII production in CIA might also be attributable
to direct suppression of TCR/CD28 signaling as we observe
that ICOS and CD154 expression is compromised in T cells
treated with Rac1 peptide. Sequential upregulation of these
two proteins plays a requisite role in providing costimula-
tory signals required for efficient B-cell antibody produc-
tion and isotype class switching [42,43]. Blockade of either
ICOS or CD154 interaction with their respective ligands is
protective in murine models of arthritis and suppresses
autoantibody production [33-36]. In RA, synovial T-cell
expression of CD154 can also promote antigen-independent
activation of macrophages and stromal cells [44-46].
Finally, Rac1 inhibition may interfere with anti-bCII anti-
body production via effects on DCs. Although this possibil-
ity is not addressed in our studies, Rac1-deficient CD8α+
DCs, but not Rac2-deficient DCs, fail to migrate to second-
ary lymphoid organs and cannot establish stable contacts
with naïve T cells [22]. DCs from mindin-/- mice, which
have reduced expression of Rac1 and Rac2, also have
impaired priming capacity due to inefficient engagement
with T cells, in turn leading to defective humoral responses
to T cell-dependent antigens in these mice [47].
Our studies suggest that Rac1 peptide suppresses T-cell
activation and subsequent generation of inflammatory
cytokines and costimulatory proteins needed for anti-colla-
gen antibody production in CIA. Future studies will be
required not only to further define specific effects on lym-
phocytes and lymphocyte interactions with APCs but also
to consider the potential contributions of Rac2, indepen-
dently or in conjunction with Rac1, to pathology in CIA.
Structure-based studies have recently led to the develop-
ment of small-molecular-weight compounds that can spe-
cifically prevent interaction of Rac1 and Rac2 with
activating guanine nucleotide exchange factors [27,48].
These compounds can block RA FLS growth and matrix
invasion in vitro, although their efficacy in the treatment of
arthritis in vivo remains to be established.
Conclusions
We demonstrate that a cell-permeable inhibitory Rac1 car-
boxy-terminal peptide can reduce paw swelling and anti-
body production during murine experimental arthritis.
These protective effects may be attributed at least in part to
suppression of T-cell inflammatory cytokine and costimula-
tory protein expression. Conceivably, Rac1 peptide treat-
ment could augment the pharmacological activity toward
B-lineage cells of other immunosuppressive therapies, like
rituximab or atacicept, which may theoretically increase
therapeutic activity. An alternative approach that might per-
haps result in a beneficial effect on both clinical signs and
symptoms as well as joint destruction could be the suppres-
sion of Rac signaling in RA by compounds targeting both
Rac1 and Rac2 signaling. The present study supports the
rationale for future studies exploring these approaches.
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